P140/Lupuzor reached Phase III clinical trials specifically for SLE, demonstrating that peptide-based approaches are being seriously investigated as therapeutic options
References Cell Metabolism (2015) The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Lee C, Zeng J, Drew BG, et al.) Journal of Translational Medicine (2023) Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging (Wan W, Zhang L, Lin Y, et al.) Journal of Molecular Medicine (2019) MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction (Lu H, Wei M, Zhai Y, et al.) Nature Communications (2021) MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Reynolds JC, Lai RW, Woodhead JST, et al.) Frontiers in Physiology (2023) Role of MOTS-c in the regulation of bone metabolism (Yi X, Hu G, Yang Y, et al.)
Animal studies suggest it works through specific cellular signaling pathways (FAK-paxillin and ERK1/2) to ramp up this repair process
number and diameter of blood vessels, epithelization and collagen
